Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049412 | 0.85 | EPHX2 (0.43) | EPHX2MAOAGAASMN1; SMN2MAPT | |
| SCHEMBL19002619 | 0.85 | EPHX2 (0.46) | EPHX2MAOAGAASMN1; SMN2MAPT | |
| SCHEMBL10132083 | 0.83 | MAOA (0.47) | MAOAGAASMN1; SMN2MAPTNPSR1 | |
| SCHEMBL19002489 | 0.82 | EPHX2 (0.43) | EPHX2MAOAGAASMN1; SMN2MAPT | |
| SCHEMBL20665149 | 0.82 | EPHX2 (0.43) | EPHX2MAOAGAASMN1; SMN2MAPT | |
| SCHEMBL23222183 | 0.81 | EPHX2 (0.42) | EPHX2MAOAGAASMN1; SMN2NPSR1 | |
| SCHEMBL19002620 | 0.81 | EPHX2 (0.42) | EPHX2MAOAGAASMN1; SMN2MAPT | |
| Oxalic Acid SCHEMBL9795222 | 0.79 | EPHX2 (0.47) | EPHX2MAOAGAASMN1; SMN2MAPT | |
| Oxalic Acid SCHEMBL9795219 | 0.79 | EPHX2 (0.47) | EPHX2MAOAGAASMN1; SMN2MAPT | |
| SCHEMBL17335561 | 0.77 | EPHX2 (0.58) | EPHX2SMN1; SMN2MAPTNPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | EPHX2 2625/4885MAOA 4408/4885GAA 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.